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AbstrAct
Objective Non-Hodgkin’s lymphoma (NHL) is the most 
common childhood malignancy in sub-Saharan Africa. 
Survival rates for NHL are higher than 80% in high-income 
countries. This study explores treatment outcomes of 
children with NHL in Kenya, a sub-Saharan low-income 
country, and the association between health insurance 
status at diagnosis and treatment outcomes.
Design This was a retrospective medical records study. 
All children diagnosed with NHL in 2010, 2011 and 2012 
were included. Data on treatment outcomes and health 
insurance status at diagnosis were collected.
results Of all 63 patients with NHL, 35% abandoned 
treatment, 22% had progressive or relapsed disease, 14% 
died and 29% had event-free survival. Most patients (73%) 
had no health insurance at diagnosis. Treatment outcomes 
in children with or without health insurance at diagnosis 
differed significantly (p=0.005). The most likely treatment 
outcome in children with health insurance at diagnosis 
was event-free survival (53%), whereas in children without 
health insurance at diagnosis it was abandonment of 
treatment (44%). Crude HR for treatment failure was 3.1 
(95% CI 1.41 to 6.60, p=0.005) for uninsured versus 
insured children. The event-free survival estimate was 
significantly higher in children with health insurance at 
diagnosis than in patients without health insurance at 
diagnosis (p=0.003). Stage of disease at diagnosis was 
identified as a confounder of this association (adjusted 
HR=2.4, 95% CI 0.95 to 6.12, p=0.063).
conclusions Survival of children with NHL in Kenya 
is much lower compared with high-income countries. 
Abandonment of treatment is the most common cause 
of treatment failure. Health insurance at diagnosis was 
associated with better treatment outcomes and survival.
IntrODuctIOn
Non-Hodgkin’s lymphoma (NHL) is the 
most commonly diagnosed paediatric malig-
nancy in sub-Saharan African countries. This 
increased incidence of NHL, compared with 
the rest of the world, is related to endemic 
malaria in many parts of this region. The 
development of Burkitt’s lymphoma, a 
subtype of NHL, is associated with Epstein-
Barr virus and chronic malaria infection.1 2
Childhood cancer survival rates have 
increased substantially in the last decades, 
especially for patients with NHL in high-in-
come countries. In 1975, the 5-year survival 
rate for patients with NHL younger than 15 
years was 45%, which improved to 87% in 
2010.3 Reported NHL survival rates in low and 
middle-income countries vary considerably 
and are particularly poor in Africa compared 
with high-income countries.4–10 In Malawi, the 
reported survival of children with Burkitt’s 
lymphoma was 33%.11 In North Africa, a 
survival rate of 61% was reported in chil-
dren with Burkitt’s lymphoma from Algeria, 
Cameroon, Madagascar, Morocco, Tunisia 
and Senegal.12
The gap in NHL survival between high 
versus low and middle-income countries can 
be related to many factors including higher 
What this study hopes to add?
 ► In this sub-Saharan African study, most children with 
NHL had no health insurance at diagnosis.
 ► Health  insurance at diagnosis was associated with 
reduced treatment abandonment and better survival 
of children with NHL.
 ► This study illustrates the need for universal health 
coverage in low and middle-income countries 
to improve access to healthcare services and 
health outcomes of its populations.
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Original article
What is already known on this topic?
 ► Poor childhood cancer survival in low and middle-
income countries is mainly due to treatment 
abandonment.
 ► Non-Hodgkin's lymphoma (NHL) is the most common 
childhood cancer in sub-Saharan Africa.
 ► No study has investigated the association between 
health insurance status at diagnosis and treatment 
outcomes of children with NHL.
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prevalence of malnutrition and low socioeconomic status 
in the latter countries.4–10 When families are poor, their 
access to healthcare services may be limited as required 
treatment at specialised cancer centres may be too expen-
sive. Access to health insurance, which could help cover 
medical expenses, may be limited for the poor majority in 
low and middle-income countries. Lacking health insur-
ance may cause delays in health-seeking behaviour, 
resulting in advanced disease stages at diagnosis, and it 
may force poor parents to abandon potentially curative 
cancer treatment for their children.4–10
To the best of our knowledge, no studies have 
been conducted that focus on associations between 
health insurance status at diagnosis and treatment 
outcomes in patients with NHL in high, middle or low-in-
come countries. Our study explores treatment outcomes 
of children with NHL in Kenya, and its association with 
health insurance status at diagnosis.
MethODs
setting
Kenya is an equatorial country in East Africa with a popu-
lation of 45 million people. Nearly half of the citizens 
are living below the poverty line. Kenya has a relatively 
young population as 42% of its inhabitants are between 
0 and 14 years of age.13
Since 1966, the National Hospital Insurance Fund 
(NHIF) is Kenya’s government-owned health insurance. 
Every Kenyan above 18 years is eligible to enrol in NHIF. 
Contribution for self-employed or unemployed Kenyans 
is around US$2 per month which covers inpatient 
healthcare in government hospitals of the contributor 
and nuclear family members. Contribution for Kenyans 
working in formal sector is calculated based on their 
income. Despite its affordability, less than 10% of Kenyan 
population is insured.14 15
Our study was conducted at Moi Teaching and Referral 
Hospital (MTRH) in Eldoret. MTRH has an estimated 
service area of 16–18 million people, and subsequently 
700 children under 15 years are expected to be diag-
nosed with a malignancy each year.2 However, in reality 
only 110 children are annually diagnosed with cancer.16 
MTRH has a bed capacity for 700 patients. Paediatric 
ward consists of 72 beds of which 16 are allocated for 
oncology patients supervised by one paediatrician.2 17
At MTRH, NHL diagnosis is confirmed by lymph node 
biopsy and/or fine needle aspiration. To stage the tumour, 
an additional chest X-ray, ultrasound, bone marrow aspi-
ration and cerebrospinal fluid cytology are performed. 
Tumour staging is done using the St Jude’s modification 
of Ann Arbor classification. After diagnosis is confirmed 
a chemotherapy regimen of COP reduction (cyclophos-
phamide, vincristine and prednisone) followed by eight 
courses of multimodal therapy is given every 3 weeks. 
Remission is determined with clinical and radiological 
assessment. At MTRH, lower intensity treatment is given 
compared with high-income settings, because access to 
expensive drugs (rituximab, high-dose treatments) and 
high-level supportive care are precluded. Nevertheless, 
various studies suggest that moderately intensive proto-
cols are effective in underdeveloped areas.18–21
study design
This was a retrospective medical records study. Inclusion 
criteria were: all children between 0 and 16 years of age, 
who were newly diagnosed with NHL at MTRH between 
January 2010 and December 2012. Further selection of 
patients did not take place.
Sociodemographic and clinical data were extracted 
from patients’ medical records using a structured data 
collection form. Sociodemographic characteristics 
included age at diagnosis, gender, ethnicity, patients’ 
residence and NHIF enrolment. Clinical characteris-
tics included date of diagnosis, duration of symptoms 
before first hospital admission at MTRH (<1 month, 1–3 
months, >3 months), staging of disease (stages I–IV), 
time to events and treatment outcomes.
Treatment outcomes were classified as treatment aban-
donment, progressive or relapsed disease, death and 
event-free survival. According to international consensus, 
treatment abandonment entails failure to start or 
continue scheduled curative treatment during four or 
more consecutive weeks.22
Our study was approved by MTRH’s Research Ethical 
Committee.
Data analysis
Data management and analysis were performed by SPSS 
V.20. Frequency distributions, means and medians were 
calculated. Relationships between treatment outcomes 
and patients’ sociodemographic or clinical character-
istics were evaluated by χ2test and Fisher’s exact test. 
Cox regression survival analysis was applied. Event-free 
survival curves were estimated by Kaplan-Meier method. 
Log-rank test compared survival between groups. Event-
free survival was measured from date of NHL diagnosis 
until first treatment failure (treatment abandonment, 
progressive or relapsed disease and death) or last 
follow-up date. Two-sided p value less than 0.05 was 
considered statistically significant.
results
In total, 280 children were diagnosed with cancer between 
2010 and 2012, of which NHL (23%) was the most 
common malignancy. From January 2010 to December 
2012, a total of 63 patients were diagnosed with NHL. 
Table 1 illustrates patients’ sociodemographic and clin-
ical characteristics. Most children (93%) were referred 
to MTRH by other healthcare facilities at primary care 
level (75%) and secondary care level (25%). Before 
patients were admitted to MTRH for the first time, 19% 
had received potential diagnosis of NHL, while 2% had 
already received some treatment destined for NHL. Of 
44 children (70%), disease stage at diagnosis was known. 
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Table 1 Sociodemographic and clinical characteristics of 
children with non-Hodgkin’s lymphoma (N=63)
Characteristics   n (%)
  Age in years
  Mean ± SD 7.7±3.3
  Median (range) 7.8 (2–16)
Gender
  Male 45 (71%)
  Female 18 (29%)
Tribe
  Luhya 27 (43%)
  Kalenjin 20 (32%)
  Luo 8 (13%)
  Kikuyu 2 (3%)
  Kisii 2 (3%)
  Maasai 2 (3%)
  Turkana 1 (2%)
  Teso 1 (2%)
Distance to MTRH (n=62)
  <50 km 2 (3%)
  50–100 km 16 (26%)
  >100 km 44 (71%)
  Comorbidities
 Malaria 10 (26%)
  HIV 6 (14%)
  Tuberculosis 1 (2%)
Duration of symptoms before first hospital admission at 
MTRH (n=59)
  <1 month 12 (20%)
  1–3 months 24 (41%)
  >3 months 23 (39%)
Stage of disease at diagnosis (n=44)
  Stage I 3 (7%)
  Stage II 5 (11%)
  Stage III 29 (66%)
  Stage IV 7 (16%)
Health insurance (NHIF) status at diagnosis (n=62)
  NHIF 17 (27%)
  No NHIF 45 (73%)
MTRH, Moi Teaching and Referral Hospital; NHIF, National Hospital 
Insurance Fund.
Figure 1 Treatment outcome in children with non-Hodgkin 
lymphoma (n=63). 
Figure 2 Kaplan-Meier estimates of event-free survival 
in children with non-Hodgkin lymphoma (n=63). Events 
included abandonment of treatment, death, and progressive 
or relapsed disease.
Most patients presented late: stage I (7%), stage II (11%), 
stage III (66%), stage IV (16%).
Treatment outcomes are summarised in figure 1. 
Treatment abandonment was the most common treat-
ment failure, which occurred in 22 patients (35%): 9% 
abandoned prior to treatment and 91% during treat-
ment. The second most common treatment failure was 
progressive or relapsed disease which affected 14 patients 
(22%): progressive disease (64%) and relapse (36%). 
The least common treatment failure was death. Of all 
nine patients (14%) who died, cause of death was classi-
fied as malignancy related (67%) and treatment related 
(33%). Figure 2 shows the event-free survival curve of all 
63 children with NHL.
NHIF status at diagnosis was known for 62 children 
(98%). Of these 62 children, 17 (27%) had NHIF and 
45 (73%) had no NHIF at diagnosis. Among those 44 for 
which disease stage was registered, disease stages III and 
IV were more often diagnosed in uninsured (n=28/31, 
90%) than in insured (n=8/13, 62%) children (p=0.037). 
Most likely treatment outcome in children with NHIF at 
diagnosis was event-free survival (n=9, 53%), whereas 
in children without NHIF at diagnosis it was abandon-
ment of treatment (n=20, 44%). Figure 3 illustrates that 
treatment outcomes in children with or without NHIF at 
diagnosis differed significantly (p=0.005). Crude HR for 
treatment failure was 3.1 (95% CI 1.41 to 6.60, p=0.005) 
for uninsured versus insured children. Figure 4 shows 
that event-free survival estimate was significantly higher in 
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Figure 3 Treatment outcome in children with non-Hodgkin 
lymphoma per health-insurance (NHIF) status at diagnosis 
(n=62, P=0.005) 
Figure 4 Kaplan-Meier estimates of event-free survival in 
children with non-Hodgkin lymphoma per health-insurance 
(NHIF) status at diagnosis (P=0.003). Events included 
abandonment of treatment, death, and progressive or 
relapsed disease. Heavy solid line, no NHIF at diagnosis 
(n=45); solid line, NHIF at diagnosis (n=17); heavy plus, 
no NHIF at diagnosis censored; plus, NHIF at diagnosis 
censored.
children with NHIF at diagnosis than in patients without 
(p=0.003). Of those children without NHIF at diagnosis, 
many (80%) enrolled during cancer treatment at MTRH 
leading the total NHIF registration level to 85%.
Following patients’ sociodemographic and clinical 
characteristics, age, gender, distance to MTRH, dura-
tion of symptoms and disease stage at diagnosis did not 
statistically significantly impact treatment outcomes and 
event-free survival estimates. Of all these characteristics, 
only disease stage at diagnosis was a confounder of asso-
ciation between NHIF and survival (adjusted HR=2.4, 
95% CI 0.95 to 6.12, p=0.063).
DIscussIOn
This study demonstrates a survival rate of 29% in chil-
dren with NHL in Kenya which is lower compared with 
high-income countries who routinely achieve survival 
rates greater than 80%. Reasons underlying poor 
cancer survival in low-income settings include delays 
in health-seeking behaviour, poor nutritional status, 
scarcity of health facilities, healthcare system delays, 
treatment costs, inconsistent medication availability, lack 
of supportive care, lack of government prioritisation of 
cancer compared with other health issues and foremost 
treatment abandonment.22–27
Also at MTRH, the main reason for treatment failure 
was treatment abandonment with 35% of children prema-
turely stopping conventional medicine. By contrast, in 
high-income settings toxicity-related death and relapse 
are most common causes of treatment failure.23 Treatment 
abandonment seldom occurs in high-income countries, 
and if it does happen state support and intervention will 
assure that the child gets cancer treatment.22 23 Unfortu-
nately, treatment abandonment is a critical problem in 
the rest of the world. Limited financial resources play a 
crucial role in families’ decision to abandon treatment. 
In low and middle-income countries social and economic 
assistance from the state and access to health insurance 
are often absent or lacking.16 22 23
We found that the vast majority of patients with NHL 
(71%) had no health insurance at diagnosis, despite the 
existence of an affordable health insurance in Kenya. 
At MTRH, treatment outcomes of childhood patients 
with NHL with or without health insurance at diagnosis 
differed significantly. The most likely treatment outcome 
in children with health insurance at diagnosis was event-
free survival, whereas in children without health insurance 
at diagnosis it was treatment abandonment. Event-free 
survival estimate was significantly higher in children with 
health insurance at diagnosis than in patients without. With 
health insurance status making such a significant differ-
ence in treatment outcome and survival, there is a strong 
call for governmental campaigns to emphasise benefits of 
health insurance so that every Kenyan citizen gets insured.
A previous Kenyan study conducted among children 
with cancer at MTRH showed that having health insur-
ance leads to shorter delays in health-seeking behaviour.24 
Parents are more likely to seek treatment at a conven-
tional healthcare facility if they have health insurance 
than if they do not have health insurance. In the latter 
case, families may resort to complementary medicine 
first. Earlier and adequate health-seeking behaviour leads 
to early-stage disease at diagnosis which has better prog-
nosis, treatment options and improved survival. Major 
improvements would be feasible if health insurance was 
mandatory such that parents would visit conventional 
healthcare facilities first when their child is sick.15 24–26 
Also this study showed that more uninsured than insured 
children come to the hospital with a substantial delay 
manifesting in stage III or IV of disease. Disease stage 
at diagnosis was recognised as a confounder of the 
association between NHIF and survival. A likely explana-
tion is that families without health insurance report to 
conventional healthcare at a later stage of disease which 
limits chances of a positive treatment outcome. Further 
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investigation on a larger group of patients with NHL to 
explore and consolidate the relationship between NHIF 
status and disease stage at diagnosis is required.
Worldwide health coverage would contribute to breaking 
the vicious cycle of ill health and impoverishment of already 
marginalised populations. For example, poor health of a 
family member frequently reduces the caregivers’ ability 
to work and earn daily wages as the patient needs to be 
accompanied to hospital. A child with cancer can thus 
drive a family without health insurance into long-term 
poverty because land and livestock need to be sold, savings 
used and siblings’ tuition payments stopped to pay for 
cancer treatment. Consequently, a family loses their means 
of earning a living and their chance to escape poverty 
through educational achievements of its young generation. 
By contrast, insured families are better protected from the 
financial abyss caused by the disease.27 28 In most low and 
middle-income countries, the vast majority of the popu-
lation is poor and uninsured. Improving their access to 
the health sector through health insurance coverage will 
importantly prevent a loss of income and positively impact 
the nation’s economic growth.29
The importance of health coverage is also emphasised by 
the United Nations General Assembly’s unanimous accep-
tance of a ground-breaking resolution in which universal 
health coverage (UHC) is recommended for sustainable 
development. The General Assembly addresses govern-
ments to ‘urgently and significantly scale up efforts to 
accelerate the transition towards universal access to afford-
able and high quality healthcare services.’30 31 The aim 
of UHC is to ensure that all people receive medical care 
without suffering financially for it. By covering safe, effec-
tive, quality and affordable essential healthcare services, 
medicines and vaccines, UHC importantly reduces the 
financial risks which are associated with ill health and 
improves health standards and life expectancy, and protects 
household incomes.27 30 31 The World Bank supports low 
and middle-income countries by offering loans, advice and 
resources in their pursuit of UHC.27
Among our patients with NHL who abandoned treat-
ment, only 9% refused treatment, while 91% dropped out 
after treatment initiation. Timing of abandonment, either 
prior or during treatment, depends importantly on acces-
sibility of healthcare services.28 32 If families are denied 
access when their financial means are limited, more chil-
dren will abandon treatment immediately after diagnosis 
without starting treatment. For instance, in India, 67% 
of childhood patients with cancer refused treatment and 
33% departed after initially starting therapy.28 The low 
number of children refusing treatment at MTRH may 
be explained by hospital detention practices, which are 
defined as ‘refusal to release living patients after medical 
discharge is clinically indicated, or bodies of deceased 
patients, when families are unable to pay hospital bills.29 33 
Children are thus initially admitted and treated. Families 
are subsequently not allowed to take their children home 
before medical invoices are covered. This can lead to 
painful situations, where families are desperately trying 
to find money while their children are left alone inside 
hospital. After bills are paid, families will hesitate to bring 
their child back to hospital for treatment continuation 
or follow-up with the risk of high medical expenses and 
detention. Thus, hospital detention practices can further 
exacerbate treatment abandonment.15 24 29
Male gender accounts for 71% of patients in our study. 
Globally, NHL is two to three times more common in boys 
than in girls. Therefore, we cannot relate our findings to 
gender-biased seeking of healthcare, as has been docu-
mented for other malignancies.23 34 In the latter cases, 
cultural aspects may explain the male predominance. 
Kenyan culture, for instance, is a paternalistic culture 
where boys are generally more appreciated than girls. 
Girls, once married, are not considered part of the family 
anymore. The father will leave his wealth and shamba 
(farmland) to his son. Therefore, to continue the family 
line and tradition, it is important that the boy survives.35 
Yet, our NHL male/female ratio of 2.4:1 is in line with 
results from previous studies.36 37
The main limitations of our investigation were its 
small sample size and retrospective nature. Some restric-
tions of retrospective chart reviews need to be taken 
into account: only pre-existing data can be analysed, it 
cannot determine causation and some important data 
may be missing. We learnt that recording of clinical char-
acteristics, such as disease stage at diagnosis, needs to 
be rigorously improved. Additional research on a larger 
group of patients with NHL at MTRH is required before 
definitive conclusions can be drawn.
In conclusion, survival of children with NHL in Kenya 
is much lower compared with high-income countries. 
The main reason for treatment failure was abandonment 
of treatment. Health insurance at diagnosis significantly 
improved treatment outcome and survival. Based on 
our study, we recommend that government implements 
obligatory health insurance for every Kenyan citizen. This 
can be achieved by making it mandatory to register with 
NHIF when obtaining birth certificates or national iden-
tity cards at the age of 18 years old. This will help reduce 
the risk of treatment failure, increase NHL survival and 
protect families from financial suffering.
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